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Abstract
The host immune response contributes to the onset and progression of severe malaria syndromes, such as cerebral malaria.
Adjunctive immunomodulatory strategies for severe malaria may improve clinical outcome beyond that achievable with
artemisinin-based therapy alone. Here, we report that prophylaxis with inhaled nitric oxide significantly reduced systemic
inflammation (lower TNF, IFNc and MCP-1 in peripheral blood) and endothelial activation (decreased sICAM-1 and vWF, and
increased angiopoeitin-1 levels in peripheral blood) in an experimental cerebral malaria model. Mice that received inhaled
nitric oxide starting prior to infection had reduced parasitized erythrocyte accumulation in the brain, decreased brain
expression of ICAM-1, and preserved vascular integrity compared to control mice. Inhaled nitric oxide administered in
combination with artesunate, starting as late as 5.5 days post-infection, improved survival over treatment with artesunate
alone (70% survival in the artesunate only vs. 100% survival in the artesunate plus iNO group, p=0.03). These data support
the clinical investigation of inhaled nitric oxide as a novel adjunctive therapy in patients with severe malaria.
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Introduction
Cerebral malaria (CM) is a severe complication of Plasmodium
falciparum infection, characterized by coma and convulsions [1].
CM is associated with a high mortality rate, and with long-term
cognitive and neurological deficits in survivors [1–2]. Although
artemisinin-based therapy has reduced the mortality rate associ-
ated with severe malaria, the fatality rate associated with CM has
remained high (approximately 30% in adults and 18% in children)
[3–4]. It has long been recognized that the host immune response
plays an important role in modulating pathology in malaria, and
this has fueled the search for effective immunomodulatory
adjunctive therapies [5]. Unfortunately, adjunctive therapies have
yet to definitively improve clinical outcome [5–6]. A detailed
understanding of the mechanisms underlying CM may facilitate
the rational design of more effective interventions.
CM is a complex multisystem disorder that is incompletely
understood. The accumulation of parasitized erythrocytes (PEs)
within the cerebral microvasculature and an excessive inflamma-
tory response to infection are hallmarks of CM [7–9].
Fundoscopy and histopathological studies of CM cases have
demonstrated sequestration of PEs in the brain, along with
perfusion abnormalities (including vascular occlusion), hemor-
rhages, and local tissue hypoxia and ischemia [1,10–13]. Elevated
levels of inflammatory cytokines have been observed in human
CM [14–16], and elevated levels of TNF in the cerebral spinal
fluid correlated with encephalopathy in infected children [9].
Although inflammatory cytokines have been demonstrated to be
critical in experimental CM, it is unclear if inflammatory
cytokines have a causal role in human CM due to the difficulty
of conducting mechanistic studies in humans. Parasite sequestra-
tion and inflammation can lead to endothelial activation and
dysfunction. Widespread endothelial activation (including in-
creased ICAM-1 expression and disruption of cell-junction
proteins) has been observed in post-mortem studies of CM
patients [1,17,18]. Biomarkers of endothelial activation and
dysfunction, including soluble ICAM-1 (sICAM-1), von Will-
ebrand factor (vWF) and its propeptide, and angiopoietin-2 (Ang-
2) were elevated, while Ang-1 (a biomarker of endothelial
quiescence) was decreased in severe and CM patients [19–25].
Further, impairment of endothelium-dependent vasodilation (a
measure of endothelial dysfunction) correlated with disease
severity in patients with malaria and was partially corrected by
the administration of L-arginine [26].
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27714Nitric oxide (NO) is a gaseous signaling molecule produced by a
family of nitric oxide synthase (NOS) enzymes that catalyze the
production of NO from L-arginine [27]. NO plays an important
role in regulating endothelium function via multiple mechanisms,
which include its action on the Ang-Tie2 system. The Ang-Tie2
system is a critical regulator of endothelial quiescence and
activation, via the interaction of Ang-1 and Ang-2 with their
cognate receptor Tie2. Ang-1 exerts anti-inflammatory effects and
promotes endothelial quiescence, while Ang-2 promotes vascular
permeability and endothelial activation [28–29]. NO can inhibit
the release of Ang-2 from its storage site in endothelial cell Weibel-
Palade (WP) bodies, and can induce the expression of Ang-1
[30–32]. NO also promotes endothelial quiescence by inhibiting
inflammatory responses, decreasing the expression of cell adhesion
molecules on the endothelium, and limiting intravascular platelet
and leukocyte aggregation [33–34]. NO also acts as a vasodilator
[35]. In the context of CM, these actions may reduce
inflammation, decrease PE, platelet and leukocyte adhesion in
the brain microvasculature, limit endothelial dysfunction, and
improve cerebral blood flow [36].
Observations in children and adults with malaria suggest a
correlation between impaired NO bioavailability and disease severity.
Low NO levels, reduced NOS2 expression, low plasma concentra-
tions of L-arginine, and increased levels of ADMA (an inhibitor of
NOS) [26,37–39], all have been associated with more severe disease.
P. berghei ANKA (PbA) infection in susceptible mice is a well
described model that recapitulates several important features of
human CM [40–43]. PbA-infected mice show signs of neurological
dysfunction, including seizures, paralysis and coma. Systemic
inflammation, brain hemorrhages, and vascular occlusion (by both
leukocytes and PEs) have been observed in this model [40–43]. A
recent report by White et al. [44] questioned the utility of the PbA-
induced experimental CM model mainly based on an assertion
that experimental CM is primarily driven by an immunological
response involving little or no sequestration of parasites in the
brain while human CM results from obstruction of microvessels in
the brain by adhesion of PEs. However, this assertion has been
challenged by several groups who agree that both processes are
likely to contribute to CM pathogenesis in humans, and that the
experimental CM model is a valuable tool for dissecting the
mechanisms underlying the pathogenesis of CM that are not
feasible to study in humans [41–43,45–46].
Our objective for this study was to investigate whether inhaled
NO (iNO) administration could reduce endothelial activation and
protect mice from experimental CM. We chose to deliver iNO,
rather than an NO donor, since this mode of NO administration
does not produce systemic hypotension, is safe and easy to
administer, and is already FDA-approved for use in infants for the
treatment of respiratory failure, hypoxia, and pulmonary hyper-
tension [47]. These properties make iNO an attractive candidate
for transition to human trials.
We demonstrate that prophylactic administration of iNO to
mice infected with PbA was associated with reduced systemic
inflammation, endothelial quiescence, decreased ICAM-1 expres-
sion, reduced parasite accumulation in the brain, and preserved
vascular integrity. Inhaled NO significantly improved survival
when initiated in combination with artesunate as late as 5.5 days
post infection.
Results
Inhaled NO prolongs survival in a mouse model of CM
To investigate the effects of iNO in experimental CM, mice
were infected with PbA and administered gaseous NO continu-
ously (80 ppm in air) in a prophylactic manner. NO2 levels were
maintained at about 1.0 ppm, with peak NO2 levels never
exceeding 2.0 ppm.
Mice receiving iNO showed a modest but reproducible and
highly significant enhancement in survival (p=0.0007; Figure 1A)
compared to control mice breathing air alone. Parasitemia
(Figure 1B), weight (data not shown), and hematocrit (Figure 2C)
did not differ significantly between the two groups.
Although NO itself is a short-lived molecule in the body with a
half-life of less than one second, we observed systemic effects when
NO was administered by inhalation in our model. Nitrite is a
stable oxidation product of NO and was previously considered to
be an inert metabolite of NO. However, recent evidence suggests
that nitrite is a bioactive product that functions as an important
vascular NO reservoir and endocrine transporter for NO [48].
Nitrite can generate NO by its reduction along a pH and oxygen
gradient, serving as an acidic and hypoxic NO reservoir both in
the vasculature and in tissue. To test the hypothesis that nitrite can
function as an NO delivery system in our model, we administered
nitrite to PbA-infected mice in their drinking water, starting on the
day of infection. Mice receiving nitrite had a significant survival
advantage over control mice similar to that observed with iNO
(Figure 1D). As with iNO, parasitemia and weight did not differ
significantly between control and mice receiving nitrite (Figure 1E
and data not shown).
Inhaled NO reduces systemic inflammation and
endothelial cell activation
A dysregulated systemic cytokine response, characterized by
high circulating levels of pro-inflammatory cytokines, has been
associated with poor clinical outcomes in human malaria infection
[49–51]. Mice susceptible to PbA also develop a marked systemic
pro-inflammatory response during infection [52]. To determine if
iNO could modulate malaria-induced inflammation, we assessed
plasma levels of pro-inflammatory cytokines on day 5 post-
infection. Compared to control mice, mice receiving iNO
prophylactically had significantly reduced plasma levels of IFNc,
TNF and MCP-1 (p=0.0004, p=0.0035, p=0.018 respectively;
Figure 2). Elevated levels of these cytokines have previously been
associated with poor outcome in human and murine models of
malaria [49,51,52]. Thus, iNO was able to reduce malaria-
associated systemic inflammation in experimental CM.
Vascular endothelium activation is also a central feature of both
human and experimental CM [18]. The constitutive interaction
between Ang-1 and Tie2 functions to maintain endothelium
quiescence. Ang-2 antagonizes the Ang-1-Tie2 interaction, and
sensitizes the endothelium to inflammatory stimuli such as TNF
[53]. Elevated levels of Ang-2 and a higher Ang-2/Ang-1 ratio
have been reported in patients with CM, as have other markers of
endothelial activation including sICAM-1 and vWF [18–24,54].
Levels of sICAM-1 and vWF were significantly reduced in mice
receiving iNO (p=0.0094 and p=0.0089 respectively), suggesting
less endothelial activation and a reduction in the exocytosis of WP
bodies (Figure 3A-B). Levels of Ang-1 were significantly higher in
iNO treated mice compared to those receiving air (p=0.039;
Figure 3C). Due to a lack of murine reagents, it was not possible to
measure Ang-2 protein levels in plasma. To determine the effects
of iNO on Ang-2, we measured Ang-2 and Ang-1 mRNA levels in
brain homogenates of infected mice using quantitative real-time
PCR (qRT-PCR). Mice treated with iNO had lower Ang-2/Ang-1
mRNA ratios than mice receiving air, indicating a shift in the Ang-
2 to Ang-1 balance towards a more quiescent endothelium
(p=0.028; Figure 3D). Additionally, the ratio of plasma levels of
vWF (also released from WP bodies) to Ang-1 were significantly
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83.56) for air vs. 0.7481 (0.135–2.17) for NO, p=0.0289).
Collectively, these data indicate that iNO reduced endothelial
activation in vivo in this model.
Inhaled NO reduces ICAM-1 expression and parasite
accumulation in the brain
Parasite sequestration in the cerebral microvasculature is
frequently observed in post-mortem examinations of fatal cases
of human CM, and is thought to be a contributing factor to the
development of CM [1,55]. The role of cerebral accumulation of
PbA-PEs in experimental CM has been more controversial. Most
blocked vessels during experimental CM contain a mixture of PEs
and leukocytes, which suggests that PbA-PE accumulation alone
may not be sufficient to cause blockage of microvessels in the brain
during infection [56–58,44]. However, accumulation of PbA-PEs
has been observed in cerebral and cerebellar capillaries of mice
displaying signs of experimental CM [56-57,59–61]. To examine if
iNO reduces PbA-PE accumulation in the brain, we performed
luminometer imaging of the brains of mice infected with PbA
Figure 1. Prophylactic inhaled NO prolongs survival in mice infected with P. berghei ANKA. Kaplan Myer survival curves are shown for
C57BL/6 mice infected with 1x10
6 P. berghei ANKA PEs and treated in (A-C) with either 80 ppm NO (red) or air (black) starting one day prior to
infection, or in (D-E) with either nitrite (administered in the drinking water at 500 mg/L of water, shown in red) or water (black). Survival (A and D) was
assessed twice daily. Significant differences in survival were assessed by Log rank test. For (A) p=0.0007, n=18 in air and n=20 in NO group,
representative of 5 independent experiments. For (D) p=0.0004, n=10 per group, representative of 2 independent experiments. Parasitemia levels
did not differ between the groups (B and E). Hematocrit did not differ between iNO- and air-treated groups (C).
doi:10.1371/journal.pone.0027714.g001
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matched air- and iNO-treated mice were injected with luciferin
(luciferase substrate), perfused to remove all blood and unbound
PEs, and the brains were collected and imaged. Bioluminescence
(assessed as total flux), an indication of PE accumulation in the
brain, was significantly higher in control mice as compared to
those receiving iNO, suggesting that although peripheral parasit-
emia was equal, iNO-treated mice had less PEs accumulating in
the brain (p=0.023; Figure 4 A-B). As a control, we imaged the
brains of infected BALB/c mice. BALB/c mice are more resistant
to experimental CM and do not develop neurological complica-
tions from infection [63], so one would expect to see less PE
accumulation in the brain. In comparison with parasitemia-
matched C57BL/6 mice, BALB/c mice had negligible biolumi-
nescence detected in the brain suggesting a lack of PE
accumulation (Figure 4A bottom panels).
To examine the potential mechanisms leading to reduced brain
accumulation of PbA-PEs, we assessed ICAM-1 expression in the
brains of iNO- and air-treated C57BL/6 mice. ICAM-1 is a
cytokine-inducible cell surface receptor, and a major sequestration
receptor for P. falciparum PEs in the brain [18,64]. In clinical
malaria, increased serum levels of the soluble form of ICAM-1 and
increased protein expression in the microvascular endothelial sites
have been observed [18–19,64–67]. In mice, ICAM-1 has been
shown to be upregulated by PbA infection [68–69], and ICAM-1
deficiency resulted in an improved survival from experimental
CM, which was associated with abolition of blood-brain barrier
breakdown, and a reduction in the accumulation of macrophages
in the brain and PbA-PEs in the lung microvessels [70]. Using
immunohistochemistry, we observed that ICAM-1 expression was
upregulated in the brains of infected mice as compared to
uninfected controls, with expression localized to blood vessels.
Mice treated with iNO had lower levels of ICAM-1 expression in
their cerebral vessels (Figure 4C). This finding is in agreement with
previous observations on the effect of an NO donor on ICAM-1
protein levels in the brain of PbA infected mice [71]. To quantify
the effect of iNO on ICAM-1 expression, we performed qRT-PCR
on brain extracts. Consistent with the immunohistochemistry data,
iNO treated mice had significantly lower levels of ICAM-1 mRNA
in the brain as compared to air breathing controls (Figure 4D).
Inhaled NO protects blood-brain barrier integrity
Because our data suggested that PE accumulation in the brain
and endothelial activation were reduced in mice treated
prophylactically with iNO, we investigated whether the integrity
of the blood-brain barrier was also enhanced in PbA-infected
C57BL/6 mice breathing NO. To assess vascular integrity, mice
were injected with Evans blue on day 6 post-infection. Two hours
post-injection, mice were euthanized, perfused to remove all
blood, and the brains were assessed for Evans blue extravasation as
a measure of vascular leak. iNO-treated mice had significantly
reduced levels of vascular leak and preserved blood-brain barrier
function as compared to air-breathing mice, despite having
equivalent peripheral parasitemia (p,0.0001; Figure 5A-B).
To further investigate vascular integrity and neurological injury,
we quantified (blinded to the treatment group) the number of
brain hemorrhages on day 6 post-infection. iNO-treated mice had
significantly fewer brain hemorrhages compared to controls
(p=0.0079; Figure 5C).
Inhaled NO co-administered with artesunate improves
survival over artesunate treatment alone
Any adjunctive therapy for human CM would be administered
in combination with anti-parasitic chemotherapy. Therefore, we
next examined if iNO administered in combination with
artesunate would confer improved survival over treatment with
artesunate alone. PbA-infected C57BL/6 mice were given 4 once-
daily doses of artesunate (10mg/kg/day) plus either air or 80 ppm
iNO continuously starting on day 3 post-infection, or a single dose
of artesunate plus either air or 80 ppm iNO continuously starting
on day 5.5 post-infection. On day 3 of infection mice had
detectable parasitemia but were not exhibiting any signs of CM.
On day 5.5 of infection mice had experienced significant weight
loss (56% of the mice had lost greater than 8% of their body
weight) and were exhibiting the initial signs of CM, including
hunched posture, ruffled fur, and lethargy (50% of untreated mice
succumbed to their infection within 12 hours). Mice receiving iNO
plus artesunate, starting on either day 3 (Figure 6A) or day 5.5
(Figure 6D) post-infection, had a significant survival advantage
over mice receiving artesunate alone. Methemoglobin levels
measured on day 7 post-infection did not differ between the two
Figure 2. Inhaled NO reduces systemic inflammation in mice infected with P. berghei ANKA. Heparinized saphenous vein blood was
collected on day 5 post-infection from mice that were prophylactically treated with either air or 80ppm NO. Plasma levels of (A) IFNc, (B) TNF, and (C)
MCP-1 were determined using the mouse inflammation cytometric bead array. Statistical differences were assessed by Mann-Whitney test. For (A)
p=0.0004, for (B) p=0.0035, for (C) p=0.018. Data are representative of 2 independent experiments. Plasma from uninfected mice was also tested as
a control, and levels of all 3 cytokines were below the limit of detection.
doi:10.1371/journal.pone.0027714.g002
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1.19) and for ART + iNO =1.01 (0.95–1.17), p=0.43 by Mann
Whitney test, n=11 per group). Of the mice that did not succumb
to CM, hematocrit levels (Figure 6C and 6F) were significantly
higher in mice receiving iNO compared to controls (although
parasitemia did not differ between the two groups; Figure 6B and
6E).
Discussion
Dysregulated host responses contribute to the adverse and fatal
outcomes associated with severe malaria syndromes. Adjunctive
therapies that target deleterious immune responses are a rational
approach to improve outcome for life-threatening infections.
However, relatively few adjunctive therapies have been tested for
malaria, and even fewer have shown efficacy in clinical trials
[22,72]. Here, we report that prophylactic treatment with iNO
reduced endothelial activation, inflammation, cerebral PE accu-
mulation, and neurological injury, as assessed by vascular leak and
CNS hemorrhages, in PbA-infected mice. In addition, therapeutic
administration of iNO in combination with artesunate starting as
late as day 5.5 post-infection conferred a survival advantage in an
experimental model of CM. We propose that the attenuation of
cerebral pathology in NO-breathing mice resulted, at least in part,
from reduced inflammation and preservation of endothelial
integrity.
In clinical malaria, impaired NO bioavailability and low plasma
concentrations of L-arginine were associated with disease severity
[26,38,73]. Also, recovery from severe malaria was accompanied
by improvement in endothelial function and L-arginine level in the
peripheral blood [22]. In experimental CM, restoring NO
bioavailability by administering a NO-donor or L-arginine
improves survival [71,74–75]. Gragmalia et al. reported in data
not shown that NO gas also had a protective effect [74]. Multiple
factors contribute to the development of CM, including uncon-
trolled inflammation, accumulation of PEs in the brain, and
blood–brain–barrier dysfunction. NO has been shown to regulate
inflammatory responses and endothelial activation, to protect
against vascular injury, and to improve cerebral hemodynamics,
important protective processes in the context of CM [36,71,74,75].
High levels of pro-inflammatory mediators correlate with
disease severity and fatal outcomes in malaria infection. In
agreement with the known anti-inflammatory properties of NO,
malaria-infected mice receiving iNO had lower plasma levels of
TNF, IFNc and MCP-1, inflammatory markers associated with
severe malaria [49-52]. Our data are consistent with a previous
report that administration of an NO donor to PbA-infected mice
reduced peripheral blood levels of the inflammatory biomarkers,
IL-18 and soluble CD40 [74].
Inflammatory cytokines can contribute to endothelial activation
by inducing the upregulation of adhesion molecules such as
ICAM-1, a major receptor for P. falciparum-PEs. NO has a
regulatory effect on endothelial cell adhesion molecule expression,
helping to maintain a non-adhesive endothelium [76]. In in vitro
studies, exogenous NO reduced the number of P.falciparum PEs
adherent to endothelial cells by downregulating both basal and
inflammation-induced expression of ICAM-1 [77]. We observed
reduced accumulation of PbA-PEs in the brain of mice treated
with iNO as compared to parasitemia-matched air-breathing
mice, and this reduction was accompanied by decreased levels of
ICAM-1 expression in the brain. This finding is in agreement with
a previous study showing that administration of an NO donor
reduced expression levels of ICAM-1 and PECAM and decreased
leukocyte and platelet accumulation in the brain [71]. Our study
confirms and extends these previous observations, suggesting that
NO treatment may help to reduce cerebral sequestration of PEs, a
key pathologic feature of CM. However, we have not tested
whether PbA-PEs can directly adhere to the microvessels in the
brain or whether ICAM-1 mediates the observed PbA-PE
accumulation. The accumulation of PbA-PE may occur indepen-
dently of ICAM-1. Recently, Bridges et al. proposed a novel
mechanism whereby P.falciparum PEs can indirectly adhere to
activated endothelial cells via platelets bound to large multimers of
vWF [78]. Whether the same mechanism can be applied to the
accumulation of PbA-PEs remains to be investigated. Endothelial
activation is also associated with the exocytosis of WP bodies,
which contain Ang-2, vWF, and its propeptide [30]. We, and
others, have reported that levels of Ang-2 and vWF, and the ratio
of serum/plasma Ang-2 to Ang-1 are quantitative and indepen-
dent biomarkers of malaria severity and outcome [19–25,54]. In
vitro, NO inhibits the exocytosis of WP bodies, and thus regulates
Ang-2 and vWF release [31]. We observed that mice receiving
iNO had lower plasma levels of vWF, suggesting that the
Figure 3. Inhaled NO modulates markers of endothelial
activation in mice infected with P. berghei ANKA. (A-C)
Heparinized saphenous vein blood was collected on day 5 post-
infection from infected mice prophylactically treated with either air or
80ppm NO. Plasma levels of sICAM-1 (A), vWF (B), and Ang-1 (C) were
determined by ELISA. The line represents median levels of these factors
measured in uninfected mice. (D) Quantitative real time PCR was
performed on RNA isolated from brains collected from parasitemia-
matched air or 80ppm NO treated mice on day 6 post-infection. The
copy number for ang-1 and ang-2 were determined and the ratio
between ang-2 and ang-1 is shown. The line represents the copy
number ratio in uninfected mice. Statistical differences were assessed
using Mann-Whitney. For (A) p=0.0094, for (B) p=0.0089, for (C) p=
0.039, for (D) p=0.028.
doi:10.1371/journal.pone.0027714.g003
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PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27714Figure 4. Inhaled NO reduces PE accumulation and ICAM-1 expression in the brains of P. berghei ANKA infected mice. (A)
Luminometer imaging of brains collected on day 4 post-infection from mice infected with P. berghei ANKA–GFP–luciferase PEs and prophylactically
treated with either air (left panels) or 80 ppm NO (right panels). The rainbow scale represents the relative level of luciferase activity (correlates with
parasite load). The numbers on the lower left corner are the peripheral parasitemia levels for each mouse. The bottom panels are brains from a
C57BL/6 mouse on the left and a BALB/c mouse on the right. (B) To quantify the brain bioluminescence, total flux (photons per second) was
calculated for each brain. p=0.023 by Mann-Whitney test, n=17 per group. (C) Immunohistochemistry analysis of ICAM-1 on formalin fixed brain
sections from parasitemia matched mice infected with P. berghei ANKA and prophylactically treated with either air (top panels) or 80 ppm NO (middle
panels), or uninfected mice (bottom panels). (D) ICAM-1 mRNA expression displayed as copy number was quantified by quantitative real time PCR in
the brains of parasitemia matched infected mice prophylactically treated with air or 80 ppm NO. The line represents the median copy number for
uninfected mice. p= 0.028, by Mann-Whitney, n=14 for air, n=10 for NO.
doi:10.1371/journal.pone.0027714.g004
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vivo. NO-treated mice also had higher levels of plasma Ang-1, and
a lower Ang-2 to Ang-1 mRNA ratio in the brain. Ang-1 via its
interaction with Tie2 can lead to vascular stabilization and
decreased endothelial permeability [32], and may be a contrib-
uting factor (in combination with lower PE accumulation) to the
reduction in brain hemorrhages observed in iNO-treated mice.
Collectively, our data suggest that prophylactic administration of
iNO reduced inflammation and endothelial activation, improved
vascular stability, and decreased PE accumulation in the brain,
leading to improved survival in experimental CM.
Prophylactic treatment with iNO alone conferred a significant
but modest survival advantage in this model. Much of the potential
therapeutic strategies tested in experimental CM including
ablation or blockade of cytokine signaling were applied prior to
the development of neurological signs, and were able to prevent,
but not reverse the established CM pathologies, which is when
they must be effective in clinical practice. In our study, NO
improved outcome when administered in a more clinically
relevant manner, as adjunctive therapy with artesunate even
when initiated after the onset of neurological symptoms (5.5 day
post-infection). iNO in combination with artesunate resulted in an
increase in survival from 70% to 100% compared to treatment
with artesunate alone. Mice receiving iNO also had higher
hematocrit levels compared to mice receiving only artesunate.
Oxidative damage to uninfected erythrocytes is thought to
contribute to malarial anemia [79–80]. NO is a potent inducer
of the hemoxygenase-1 and carbon monoxide pathway [81],
which may serve to reduce oxidative damage and destruction of
uninfected erythrocytes. Together, these data support the
hypothesis that modulating the host immune response may
represent an attractive adjunctive therapeutic strategy for CM,
and encourages further testing of iNO in the clinical setting.
Clinically, delivering NO by inhalation offers several potential
advantages. Inhaled NO is relatively easy to deliver (e.g. by face
mask) in resource poor settings, does not require intravenous
access, and can be quickly discontinued if adverse events are
observed. In 1999 the US FDA approved the use of iNO (up to
80 ppm) for the treatment of neonates with hypoxic respiratory
failure and based on broad clinical experience in hundreds of
thousands of patients over the past 2 decades, has been shown to
be safe and well tolerated even in critically ill patients [47,82–84].
It is important to note that with administration of iNO it is
recommended that levels of NO2 and methemoglobin should be
monitored.
While its potential ease of delivery and safety make iNO an
attractive candidate, its short half-life raise questions about its
utility to exert systemic effects in more distant target sites such as
the brain. Systemic effects of iNO have been observed in several in
vivo models, and our study demonstrates that continuous inhalation
of NO can effectively mediate systemic effects and attenuate some
of the hallmark aspects of CM in the brain. iNO can exerts
systemic effects via several possible mechanisms. iNO may bind to
heme to form NO-heme, react with thiols to produces S-
nitrosothiols, react with amine groups to form N-nitrosamines,
all of which can regenerate NO in vascular beds [85]. iNO can
also be converted into nitrite, which can convert back to NO in an
acidic or hypoxic environment [48]. Administering nitrite
improved survival in PbA-induced CM in this study, and via its
reduction back to NO, has been shown to exert beneficial effects in
cerebral ischemia-reperfusion injury, and LPS-induced shock
[86–87].
In summary, our results using an experimental model of CM,
suggest that iNO may be a promising adjunctive therapy for
human CM. This hypothesis is currently under investigation in
two independent randomized clinical trials in Uganda (one
double-blind placebo controlled NCT01255215 [88-89], and
one open label NCT01388842).
Materials and Methods
Murine model of experimental CM
P. berghei ANKA (PbA) was obtained from the Malaria Resource
Centre (MR4, Bethesda MD) and maintained by passage in naı ¨ve
mice.
Figure 5. Inhaled NO prevents loss of blood-brain barrier vascular integrity in mice infected with P. berghei ANKA. (A) Photographs of
brains from mice injected with Evans blue on day 6 post-infection. Brains from mice prophylactically treated with air (left panels) and with 80 ppm NO
(right panels). The number on the lower left corner is the peripheral parasitemia for that mouse. (B) Quantification of total Evans blue extravasationi n
the brain as an indication of vascular leak. The line indicates median Evans blue values from uninfected mice. p,0.0001 by Mann-Whitney. n=15 per
group. (C) Number of hemorrhages quantified (blinded to the treatment group) from H&E stained sections of brains collected on day 6 post-infection
from mice prophylactically treated with either air or 80 ppm NO. p=0.0079 by Mann Whitney. n=5 per group.
doi:10.1371/journal.pone.0027714.g005
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approved all experiments. Male 7–9 week old C57BL/6 mice
were purchased from Charles River. Infection was initiated by
intraperitoneal injection of freshly isolated 1x10
6 PbA PEs/mouse,
and was monitored daily for up to 15 days by determining
parasitemia on thin blood-smears stained with Diff Quik
(American Scientific Products, Mississauga, ON). Weight and
hematocrit were determined every other day. Methemoglobin
levels were measured according to a previously published method
[90], and were normalized to the air group median value. Mice
were evaluated for signs of CM including limb paralysis, seizures,
and coma, and were euthanized when moribund.
Figure 6. Inhaled NO administered in combination with artesunate confers a survival advantage over artesunate treatment alone in
experimental CM. Mice were infected with P. berghei ANKA and were treated with either medical air (grey line), 10mg/kg artesunate (black line), or
10mg/kg artesunate plus 80 ppm NO (red line) starting on day 3 (A-C) or day 5.5 (D-F) post infection. Artesunate was given once daily by i.p. injection
for 4 days starting on day 3, or once daily for one day starting on day 5.5. Air or 80 ppm NO was initiated on day 3 or day 5.5 and continued until the
end of the experiment on day 15 post-infection. (A and D) Survival was monitored twice daily. Significant differences in survival were assessed by Log
rank test. For Day 3: p=0.049 for ART + air vs. ART + NO, n=31 for ART + air, n=30 for ART + NO, and n=10 for air alone. For Day 5.5: p=0.031 for
ART + air vs. ART + NO, n=10 for ART + air, n=14 for ART + NO, and n=8 for air alone. (B and E) Parasitemia did not differ significantly between the
ART + air and the ART + NO groups. (C and F) Hematocrit was assessed on day 14 of infection in mice receiving ART + air or NO starting on day 3 (C) or
5.5 (F) post-infection. For Day 3: p,0.0001 for ART + air vs. ART + NO, n=18 per group; for Day 5.5: p=0.0002 for ART + air vs. ART + NO, n= 18 for
ART + air, n=23 for ART + NO; by Student’s t-test. ART, artesunate, NO, nitric oxide.
doi:10.1371/journal.pone.0027714.g006
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during infection. For experiments initiating treatment on day 3
post-infection, mice received 10mg/kg artesunate/day for 4 days
and breathed air or NO beginning 3 days post-infection. For
experiments initiating treatment on day 5.5 post-infection, mice
received 10mg/kg artesunate/day for 1 day and breathed air or
NO beginning 5.5 days post-infection. Mice were placed in flow-
through chambers with free access to food and water, and received
either medical air or 80ppm +/25ppm NO mixed with medical
air, continuously. Gas flow was at 10–12 L/min to minimize the
concentration of NO2. Soda lime (200 g) was placed in each
chamber to scavenge NO2.N O 2 levels were maintained
,1.5 ppm. NO and NO2 levels were measured using an
AeroNOX device (Pulmonox Medical, Alberta, Canada).
For the nitrite experiments, nitrite (Sigma) was given in the
drinking water (500mg/L made fresh daily) for the duration of the
experiment, as described [86].
Analysis of systemic inflammation and endothelial
activation
Heparinized plasma was collected via the saphenous vein and
frozen at 280uC. Plasma cytokine levels were assessed using the
mouse inflammation cytokine bead array (BD bioscience,
Mississauga, ON). Levels of Ang-1, sICAM-1, and vWF were
determined by ELISA (R&D Systems, Minneapolis, MN).
Analysis of vascular permeability
On day 6 post-infection, mice were injected intraperitoneally
with 300 ml of 2% Evans blue. 2h post-injection mice were
euthanized using isoflurane, and perfused with 20mls of PBS.
Brains were collected, photographed, and placed in formamide for
48h to extract Evans blue. Evans blue was quantified using a
spectophotometer at 605 nm and compared to a standard curve.
Whole body imaging of parasite distribution
Mice were infected intraperitoneally with 1x10
6 PEs of a
luciferase-expressing PbA (PbGFP-LUC(con)) [62]. On day 4 post-
infection, mice were anesthetized with isoflurane, injected with
100 ml of 5mg/ml D-luciferin (Caliper, Hopkinton, MA) intrader-
mally, and imaged using the Xenogen IVIS Spectrum imager
(Xenogen, Alameda, CA). Whole body images were taken
4 minutes post-injection, when the bioluminescence signal had
reached its plateau. Mice were euthanized, and perfused (20mls
PBS) to remove all the blood. Brains were collected and imaged
45 minutes post-luciferin injection. Bioluminesence was quantified
using the Living Image 4.0 software. Total flux was used as a
metric for comparison.
Histological analysis
Brains were collected on day 6 post-infection, and fixed in 4%
formalin for 3d. 4 mm slices were stained with H&E, or with a
polyclonal antibody against ICAM-1 (R&D Systems, Minneapolis,
MN), and examined blindly.
Brain qRT PCR
RNA was extracted from snap frozen brain tissue after
homogenization in TRIzol (1mL/100 mg tissue; Invitrogen,
Burlington, ON) according to manufacturer’s protocol. Extracted
RNA (1 mg/sample) was treated with DNase I (Fermentas,
Burlington, ON), and reverse transcribed to cDNA (BioRad,
Mississauga, ON). cDNA was amplified in triplicate with SYBR
Green master mix (Roche, Laval, QC) in the presence of 1 mMo f
forward and reverse primers in a Light Cycler 480 (Roche, Laval,
QC). Transcript number was calculated based on Ct as compared
to a standard curve of mouse genomic DNA included on each plate
by Light Cycler 480 software (Roche, Laval, QC), and normalized
by geometric averaging of GAPDH, HPRT and YWAHZ
expression levels, as previously described [91]. The primer
sequences (59-39) used are as follows: GAPDH, F-tcaacagcaactcc-
cactcttcca, R-ttgtcattgagagcaatgccagcc; HPRT, F-ggagtcctgtt-
gatgttgccagta, R-gggacgcagcaactgacatttcta; YWHAZ, F-agcaggca-
gagcgatatgatgaca, R-tccctgctcagtgacagacttcat; ANGPT1, F-
cctctggtgaatattggcttggga, R-agcatgtactgcctctgactggtt; ANGPT2, F-
agagtactggctgggcaatgagtt, R-ttcccagtccttcagctggatctt; ICAM, F-
tggctgaaagatgagctcgagagt, R-gctcagctcaaacagcttccagtt.
Statistical analysis
Survival studies were performed 5 times for air vs. iNO. Other
experiments were repeated at least once. Statistical significance for
survival studies was assessed by log-rank test. Other comparisons
were assessed using Mann-Whitney test. A p-value of less than
0.05 was deemed significant. Statistical analyses were performed
using GraphPad Prism software (LaJolla, CA).
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